| Finch Therapeutics Fetches $90M to Advance Microbiome Drug Pipeline | Frank Vinluan | 09/17/20 | Boston |
| Lumen Bioscience Lands $16M to Engineer “Edible” Antibody Drugs | Frank Vinluan | 09/02/20 | Seattle |
| Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More | Frank Vinluan | 08/14/20 | National |
| Seres Sets Sights on FDA After C. Diff Microbiome Therapy Scores in Phase 3 | Frank Vinluan | 08/10/20 | Boston |
| Bio Roundup: Gilead’s Pionyr Grab, Relay to IPO, Unicorn Sana & More | Sarah de Crescenzo | 06/26/20 | National |
| In Microbiome Milestone, Finch Therapeutics C. diff Pill Bests Placebo | Sarah de Crescenzo | 06/19/20 | Boston |
| Forma Therapeutics Eyes IPO to Advance Sickle Cell, Prostate Cancer Drugs | Sarah de Crescenzo | 05/29/20 | Boston |
| Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19) | Frank Vinluan | 04/22/20 | National |
| Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More | Frank Vinluan | 04/10/20 | National |
| Novome Lands $33M to Tweak a Gut Microbe Into a Metabolic Therapy | Frank Vinluan | 01/08/20 | San Francisco |
| With Yale Tech and $12M, Artizan Aims for Root Cause of Gut Disease | Frank Vinluan | 06/10/19 | Boston |
| With $35M, Whole Biome Eyes 2020 Launch of Medical Food for Diabetes | Frank Vinluan | 05/30/19 | San Francisco |
| Flagship Pioneering Unveils Kintai’s Gut Approach to Treating Disease | Frank Vinluan | 04/16/19 | Boston |
| Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More | Frank Vinluan | 03/15/19 | National |
| Kaleido Bio Downsizes IPO, Raises $75M for Microbiome Drug Tests | Frank Vinluan | 02/27/19 | Boston |
| Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More | Ben Fidler | 02/08/19 | National |
| Seres Lays Off 30% of Staff, CSO Leaves After Pipeline Review | Corie Lok | 02/07/19 | Boston |
| Microbiome Startup uBiome Expands into Drug Research with $83M | Frank Vinluan | 09/21/18 | San Francisco |
| Trump v. Drug Makers? And 6 More Burning Biopharma Questions for 2018 | Alex Lash | 01/02/18 | National |
| Flagship Bags $618M, Its Largest Raise Ever, For a New Startup Crop | Corie Lok | 12/20/17 | Boston |
| Bio Roundup: Nobel Pursuit, Fundraising Fruit, A Rhythmic IPO & More | Alex Lash | 10/06/17 | National |
| Ex-Cubist CEO Bonney Emerges at Kaleido, Flagship’s Latest Microbiome Startup | Ben Fidler | 09/18/17 | Boston |
| Akili, Emulate, Ginkgo & More: The Innovation at the Intersection Award Finalists | Corie Lok | 09/18/17 | Boston |
| Dealmaker, Thought Leader & More: The X of the Year Xconomy Award Finalists | Corie Lok | 09/15/17 | Boston |
| Evelo Bio Raises $50M Round to Bring Microbiome Drugs Into Trials | Frank Vinluan | 07/11/17 | Boston |
| Bio Roundup: Trumpcare Is Mean, SCOTUS Says Go, Merck’s Myeloma No | Ben Fidler | 06/16/17 | National |
| Bio Roundup: Trump Budget, FDA Chief, CAR-T Qs, CRISPR Cash, & More | Alex Lash | 03/17/17 | National |
| With FDA’s Blessing, Seres Preps New “Pivotal” Microbiome Drug Trial | Frank Vinluan | 03/16/17 | Boston |
| FDA Turmoil, Biology Mystery On List Of Hurdles For Microbiome Drugs | Ben Fidler | 02/14/17 | New York |
| Bio Roundup: Travel Ban, Pharma in DC, Biogen Splits, PCSK9 Wins | Ben Fidler | 02/03/17 | National |
